On Wednesday, Shares of Bank of America Corporation (NYSE:BAC), gained 1.45% to $16.74.
Dean Athanasia, president of Preferred and Small Business Banking and co-head of Consumer Banking at Bank of America, will take part in the Deutsche Bank Global Financial Services Investor Conference on Wednesday, June 3 at 2:15 p.m. Eastern Time.
On other hand, Top U.S. solar installer SolarCity Corp on Thursday said it has partnered with Bank of America on a $200 million fund that will enable smaller investors such as regional banks to finance the company’s residential solar systems, according to Reuters.
The move is aimed at bringing new capital into the fast-growing rooftop solar industry and ultimately reducing the cost of that capital, SolarCity’s chief executive, Lyndon Rive, said.
“That will bring many more investors and then more competition, and then that will reduce the cost,” Rive said in an interview.
SolarCity and other solar financing companies for years have raised funds of $100 million or more to finance their rooftop systems from major corporations such as Google and U.S. Bancorp. These so-called tax equity funds allow the companies to claim the lucrative federal tax credits for solar energy systems. The funds generate returns of between 8 and 10 percent. Reuters Reports.
Bank of America Corporation, through its auxiliaries, provides banking and financial products and services for individual consumers, small and middle market businesses, institutional investors, large corporations, and governments worldwide.
Shares of Ceres, Inc. (NASDAQ:CERE), skyrocketed 74.40% to $2.93, during its last trading session.
Ceres, has been awarded a U.S. patent for a genetic sequence derived from soybean, covering uses of the gene in areas such as research, product development and plant transformation. The company believes that its gene is useful in regulating key biosynthetic processes that are the target of a class of commercial herbicides. Ceres plans to offer other seed companies a commercial license to the innovation, counting an opportunity for exclusivity in certain crops.
Richard Hamilton, President and CEO of Ceres, said that the company is presently evaluating the potential market for this gene among soybean seed companies and the use of its patented invention in the development and production of improved soybean varieties.
Ceres’ biotechnology platform, which has proven to enhance crop productivity, raise quality, reduce crop inputs and improve cultivation on marginal land, has broad application across multiple markets and crops.
Ceres, Inc., an agricultural biotechnology company, develops and sells energy crops to produce renewable bioenergy feedstocks in North America. The company’s energy crops comprise sweet sorghum; high biomass sorghum for the generation of renewable electric power and the creation of cellulosic biofuels; switchgrass, a perennial grass; miscanthus, a tall perennial grass for use as an energy crop.
At the end of Wednesday’s trade, Shares of Opexa Therapeutics, Inc. (NASDAQ:OPXA), surged 34.81% to $0.52.
Opexa Therapeutics, declared that Neil K. Warma, President and Chief Executive Officer, will present at the 2015 Marcum Microcap Conference on Thursday, May 28, 2015, at 11:30 a.m. EDT in the Plymouth Room. The conference will be held at the Grand Hyatt New York Hotel in New York, NY.
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases, such as neuromyelitis optica (NMO) based on its proprietary T-cell technology.
Finally, Johnson & Johnson (NYSE:JNJ), ended its last trade with 0.31% gain, and closed at $101.13.
Johnson & Johnson (JNJ) will take part in the Goldman Sachs 36th Annual Global Healthcare Conference on Thursday, June 11, at the Terranea in Rancho Palos Verdes, CA. Sandi Peterson, Group Worldwide Chairman will represent the Company in a session planned at 10:00 a.m. (Pacific Time).
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
